Corticosteroid responsive disorders are conditions generally inflammatory disorders which respond to corticosteroid treatment. Corticosteroid responsive disorders are a broad spectrum of diseases ranging from dermatology conditions such as Atopic dermatitis, Psoriasis, Seborrhoeic dermatitis, eczema, lupus erythematosus to autoimmune diseases such as Hashimoto's encephalopathy, autoimmune retinopathy, asthma, allergic rhinitis and others.
Corticosteroid-Responsive Disorders Market: Drivers and Restraints
The rising incidences of corticosteroid responsive disorders and their broad spectrum and distribution is the prime driver of the corticosteroid-responsive disorders market. According to validated clinical data, Allergic rhinitis affects the largest number of people and has a prevalence between 10–30% of people in any given year. According to the world health organization, Asthma affected 358 million people globally in 2015 up from 183 million in 1990 and was responsible for 397,100. The growing rates of asthma and its spread to low age groups is driving a large market. Dermatitis affects 245 million people in 2015 and Atopic dermatitis being the most common type. According to the Centers for Disease Control and Prevention it affects about 10–30% of people in the U.S. Atopic dermatitis affects nearly 7% of people at some point in their lifetime.
The growing geriatric population provides a strong impulse for the growth of the market. The number of people aged 60 years or older is expected to rise from 900 million to 2 billion between 2015 and 2050, representing a growth from 12% to 22% of the total global population, according to recent World Health Organization report.
The growing R&D intensively and strong development pipeline are other drivers of the growth of the corticosteroid-responsive disorders market. Attractive increment in reimbursement offered for these group of diseases owing to their severity under Medicare is projected to drive the demand for corticosteroid-responsive disorders. The Part B and Part D of the U.S. Medicare incremented REIMBURSEMENT value, if therapy is done at point of care rather than at a hospital to avoid greater expenditure associated with hospital visits. This move is anticipated to promote growth of the the home care end-user segment.
However the constraints such as high cost, and side effects is hampering the corticosteroid-responsive disorders market. Corticosteroid-responsive disorders treatment products suffer from side effects including osteoporosis, hypertension, diabetes, weight gain, increased vulnerability to infection, cataracts and glaucoma and others is hampering their adoption.
Corticosteroid-Responsive Disorders Market: Segmentation
To gain a comprehensive and a better understanding of the future market equity, the corticosteroid-responsive disorders report is segmented based on indication, drug class and end users.
Based on indication, the global corticosteroid-responsive disorders market is segmented into:
Based on drug class, the global Corticosteroid-Responsive Disorders market is segmented into:
Based on route of administration, the global Corticosteroid-Responsive Disorders market is segmented into:
Based on end users, the global Corticosteroid-Responsive Disorders market is segmented into:
Corticosteroid-Responsive Disorders Market: Overview
Based on regions, the global corticosteroid-responsive disorders market is classified into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East & Africa, and Asia Pacific market excluding Japan. North America led by U.S. is expected to dominate the global corticosteroid-responsive disorders market owing to large purchasing power, large prosperous and ageing population, and attractive reimbursement rates.
The Europe corticosteroid-responsive disorders markets is expected to be led by the Germany, France, Italy, Spain, Portugal and the UK. The Latin America and the Middle East and Africa corticosteroid-responsive disorders market is constrained due to the low healthcare expenditure and poor economic conditions. The Middle East and Africa corticosteroid-responsive disorders market is projected to be dominated by the gulf economies of UAE, Saudi Arabia, and Kuwait owing to their large wealth relative to the African nations.
The Asia Pacific market is expected to expand at a furious pace owing to growing research and development expenditure and the large economic growth. The growing economy of China, and India is expected to drive a large market adoption.
Some of the major players in the global corticosteroid-responsive disorders market are Avik Pharmaceuticals Ltd., Cipla Limited, Bristol-Myers Squibb Co., Mylan Laboratories Limited, Teva Pharmaceutical Industries, Pfizer Inc. and others.
The corticosteroid-responsive disorders report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global Corticosteroid-Responsive Disorders report covers exhaustive analysis on:
Regional analysis includes